EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma

Julian Hübner, Rhonda McFleder, Chi Wang Ip, Miriam Alb, Hermann Einsele, Michael Hudecek, Thomas Nerreter

Current Protocols · 2026-11 · 6 (11)

DOI: 10.1002/cpz1.70503 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Protocols, online erschienen am 30.10.2026. Verfasst von Julian Hübner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Cellular Immunotherapy, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, Adoptive, Brain Neoplasms, Receptors, Chimeric Antigen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most lethal primary brain tumor in adults, and despite intensive research efforts, effective therapeutic breakthroughs remain elusive. Consequently, the standard of care has remained largely unchanged for nearly 30 years, underscoring the need for robust preclinical models to evaluate experimental therapies. One particularly promising approach is chimeric antigen receptor (CAR) T cell therapy, which has demonstrated remarkable success in several hematologic malignancies but has not yet achieved comparable efficacy in solid tumors. This article describes the generation of orthotopic GBM xenografts in NSG mice, including anesthesia, surgical procedures, and postoperative care, followed by locoregional delivery of human CAR T cells into the lateral ventricle and subsequent assessment of therapeutic efficacy. Together, these protocols provide a reliable platform for evaluating GBM‐directed CAR T cell therapies in both basic and translational research. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Intracranial tumor implantation Basic Protocol 2 : Intraventricular CAR T cell administration Support Protocol 1 : Bioluminescence imaging of xenografts Support Protocol 2 : Endpoint analysis of residual tumor burden by flow cytometry

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmunotherapy, AdoptiveBrain NeoplasmsReceptors, Chimeric AntigenXenograft Model Antitumor AssaysAnimalsHumansMiceMice, SCIDDisease Models, AnimalT-Lymphocytes

Stichwörter der Autor:innen

CAR T cellsbioluminescenceflow cytometryglioblastomastereotactic surgery

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Chair of Cellular Immunotherapy, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany.
  • Department of Neurology, University Hospital Würzburg, Würzburg, Germany.
  • Department of Medicine II, University Hospital Würzburg, Würzburg, Germany.

Zitieren

APA

Hübner, J., McFleder, R., Ip, C. W., Alb, M., Einsele, H., Hudecek, M., & Nerreter, T. (2026). An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma. Current Protocols, 6(11). https://doi.org/10.1002/cpz1.70503

Vancouver

Hübner J, McFleder R, Ip CW, Alb M, Einsele H, Hudecek M, et al. An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma. Current Protocols. 2026;6(11). doi:10.1002/cpz1.70503

BibTeX
@article{Hbner2026,
  author = {Hübner, Julian and McFleder, Rhonda and Ip, Chi Wang and Alb, Miriam and Einsele, Hermann and Hudecek, Michael and Nerreter, Thomas},
  title = {An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma},
  journal = {Current Protocols},
  year = {2026},
  volume = {6},
  number = {11},
  doi = {10.1002/cpz1.70503}
}
Kostenlos starten →